Cardiovascular disorders are the leading cause of mortality worldwide. Despite many years of intense research and development to ameliorate its causes and consequences, this is an area of very large unmet medical need.

Myocardial infarction (MI), as well as other clinical conditions with prominent episodes of ischemia followed by reperfusion, usually causes severe pain that in itself often worsens the clinical outcome.

Eribis Pharmaceutical AB has discovered a series of novel peptides with prominent tissue protective effects in conditions of ischemia-reperfusion. This property is accompanied with potent and efficient analgesic properties. Therefore, it is anticipated that the peptides may be developed into an important new category of drugs to treat acute myocardial ischemia (MI) as well as for surgical preconditioning.